Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectivehENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewSystemic therapies for pancreatic cancer--the role of pharmacogeneticsAn Overview of Genetic Changes and Risk of Pancreatic Ductal AdenocarcinomaThe Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem CellsGenome-wide association study of survival in patients with pancreatic adenocarcinomaPharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 exprAssociation of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.Chemotherapy outcomes for the treatment of unresectable intrahepatic and hilar cholangiocarcinoma: a retrospective analysis.Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.Personalized therapy for pancreatic cancer: Myth or reality in 2010?Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.A replication study and genome-wide scan of single-nucleotide polymorphisms associated with pancreatic cancer risk and overall survival.dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational StudyHuman Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.Uptake carriers and oncology drug safety.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Pharmacogenetics of chemotherapy efficacy in breast cancer.Pancreatic cancer - cost for overtreatment with gemcitabine.Adjuvant pharmacotherapy in the management of elderly patients with pancreatic cancer.Role of solute carrier transporters in pancreatic cancer: a review.Pharmacogenomics in the treatment of lung cancer: an update.Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study.Nucleoside analogs: ready to enter the era of precision medicine?Molecular predictors of gemcitabine response in pancreatic cancer.Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients.Preoperative therapies for resectable and borderline resectable pancreatic cancer.Patient-Specific Pluripotent Stem Cells in Doxorubicin Cardiotoxicity: A New Window Into Personalized Medicine.Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer.Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
P2860
Q26752368-65A856A6-581E-40FB-BD3B-6692329F9DECQ26862139-A75D683A-74F2-4D24-A769-1CE489A92088Q27021716-ADE40B5B-9E73-48A3-AE6D-CE284C2528D0Q28076342-FD3BC190-CC9A-494A-8EC7-4D3EEEB3D8BFQ28550040-FBA1AFF8-F034-4224-9CEA-694C07C24296Q28943489-81CC8B26-BEA3-4226-A263-02937E76B10EQ30728815-ABD9B0A7-FD12-41B7-83EE-A86FBDA1EB57Q34254837-0F202D35-8A0E-4CE3-AF4D-1612EF41ECA0Q34408283-12306AEF-665B-41DD-BC78-CEA6DF1CA39EQ34474400-675086C9-205D-4F11-9C41-EF9CA178D0F0Q35048269-F9C420DE-7C7F-428E-AB3A-5B20CFC218ABQ35066350-8245271E-BEBE-4B36-A28E-389457F7785FQ35584339-7259CBDE-330D-4E20-8116-50A4D49D49E2Q35715498-97E7143A-5D1C-48AB-AA6E-BC05D786A371Q36003248-94382D47-1E92-477B-8A90-3C4D07126E30Q36097060-0ABFCF4A-75D8-416A-9707-7689119B649BQ36342657-9CD4857A-AACB-4751-BFF8-08F1F5670DB6Q36525188-B80DF5C5-FA7B-413A-B738-7E940ACA4B1CQ36600132-196983FA-7F0B-44A7-B488-8E02DCBEDDC5Q37207004-F4AC7672-F365-489B-94C6-4C482B4E7178Q37342736-8E47027B-074A-4888-876B-DE7E456679CEQ37663396-9A5EF0F3-576B-46D2-A569-5823AC5E6A25Q37876401-6C3847F6-F5AC-4CE3-BDDC-003F39A04D17Q38003703-31E57576-582C-4A90-86A3-50D96268064BQ38067828-E70BF471-B12F-4685-84F9-3C8ABDDBA7A7Q38075827-5E88B8D0-6136-4FD3-9269-D0331E42C6CFQ38236028-13968F79-BF02-4FB7-9B2B-40DB85BD9B6AQ38596926-10D372AA-5EB7-49AF-88B1-DBE248CB79D0Q38805564-8318DF69-90F9-4561-BF08-A13F87BF60C2Q38842938-8BC4B9E1-3DFC-4825-8EA1-44849BB78FD6Q39250668-2DBBC80E-F292-4A38-B06B-A57687C67D9EQ40633085-BE8EBF3E-3ADE-484E-9553-69E9EFF46A16Q41836511-BDEB56D5-8239-4723-A7E1-39AED881D97DQ42130469-716AC565-F3BC-4F22-B53E-521288CB84DBQ42486793-AC82F5C8-252D-45AD-9917-4D2267B4B33FQ42725709-384C8DB4-A653-41C9-8283-D0FF33EC8AD0Q43631694-9BD7CA4D-B3D1-4430-B56F-1878896771ABQ44546647-1F972E30-859A-44F1-ABB5-1FC2B07BC46EQ45220444-20F66989-59C5-485C-8D41-A8713E213DF5Q47102782-95C5B37A-2B7C-4576-AD63-809AC590D815
P2860
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Single nucleotide polymorphism ...... er survival and drug toxicity.
@ast
Single nucleotide polymorphism ...... er survival and drug toxicity.
@en
Single nucleotide polymorphism ...... er survival and drug toxicity.
@nl
type
label
Single nucleotide polymorphism ...... er survival and drug toxicity.
@ast
Single nucleotide polymorphism ...... er survival and drug toxicity.
@en
Single nucleotide polymorphism ...... er survival and drug toxicity.
@nl
prefLabel
Single nucleotide polymorphism ...... er survival and drug toxicity.
@ast
Single nucleotide polymorphism ...... er survival and drug toxicity.
@en
Single nucleotide polymorphism ...... er survival and drug toxicity.
@nl
P2093
P2860
P1476
Single nucleotide polymorphism ...... er survival and drug toxicity.
@en
P2093
Donghui Li
James L Abbruzzese
Milind Javle
Motofumi Tanaka
Taro Okazaki
P2860
P304
P356
10.1158/1078-0432.CCR-09-1555
P407
P577
2009-12-22T00:00:00Z